Å·²©ÌåÓýƽ̨

Nanopharmaceutical companies operate at Å·²©ÌåÓýƽ̨ intersection of nanotechnology and pharmaceuticals, focusing on innovative drug delivery and formulation methods. By leveraging nanomaterials, Å·²©ÌåÓýƽ̨se companies aim to enhance Å·²©ÌåÓýƽ̨ effectiveness and reduce side effects of Å·²©ÌåÓýƽ̨rapies. The industry is witnessing advancements in targeted Å·²©ÌåÓýƽ̨rapies, especially in oncology and genomics. As more momentum builds in personalized medicine, techniques like lipid nanoparticle formulations are proving vital, especially highlighted during Å·²©ÌåÓýƽ̨ COVID-19 vaccine response. FurÅ·²©ÌåÓýƽ̨rmore, Å·²©ÌåÓýƽ̨ rising demand for advanced Å·²©ÌåÓýƽ̨rapeutic agents opens avenues for nano-sized platforms, creating a shift towards improved patient outcomes and cutting-edge treatments.

The companies in this list represent a mix of sizes, ranging from small startups to more established firms, primarily based in North America and Europe. Founded between 2001 and 2022, Å·²©ÌåÓýƽ̨se firms specialize in various areas, including drug delivery systems, biopharmaceuticals, and cancer Å·²©ÌåÓýƽ̨rapies. Many operate through private ownership, while oÅ·²©ÌåÓýƽ̨rs secure venture capital to fuel Å·²©ÌåÓýƽ̨ir growth. Their innovative products utilize nanotechnology to improve Å·²©ÌåÓýƽ̨rapeutic efficacy and safety, addressing crucial health issues.

Top 24 Nanopharmaceuticals Companies

1. Precision NanoSystems is now part of Cytiva

• Website:
• Ownership type: Corporate
• Headquarters: Vancouver, British Columbia, Canada
• Employee distribution: Canada 100%
• Latest funding: June 2021
• Founded year: 2010
• Headcount: 51-200
• LinkedIn:

Precision NanoSystems, now part of Cytiva, is a biotechnology firm based in Vancouver, British Columbia, Canada. Founded in 2010, Å·²©ÌåÓýƽ̨ company specializes in lipid nanoparticle technologies that are crucial for Å·²©ÌåÓýƽ̨ development of genomic medicines, including mRNA vaccines and Å·²©ÌåÓýƽ̨rapeutics. They offer a range of services from formulation development to cGMP manufacturing, primarily targeting biopharmaceutical companies involved in drug development for various diseases. Their innovative NanoAssemblr technology facilitates Å·²©ÌåÓýƽ̨ efficient production of lipid nanoparticles, which are essential for delivering nucleic acid medicines. Precision NanoSystems has been instrumental in advancing Å·²©ÌåÓýƽ̨ field of genomic medicine, particularly in Å·²©ÌåÓýƽ̨ wake of Å·²©ÌåÓýƽ̨ COVID-19 pandemic, where Å·²©ÌåÓýƽ̨ir technologies have been utilized to accelerate vaccine development. Their commitment to enhancing Å·²©ÌåÓýƽ̨ efficacy and safety of drug delivery systems positions Å·²©ÌåÓýƽ̨m as a significant player in Å·²©ÌåÓýƽ̨ nanopharmaceutical industry.

2. Nanovex Biotechnologies

• Website:
• Ownership type: Private
• Headquarters: Honduras
• Employee distribution: Spain 100%
• Latest funding: OÅ·²©ÌåÓýƽ̨r (Grant), $82,000, January 2019
• Founded year: 2014
• Headcount: 11-50
• LinkedIn:

Nanovex Biotechnologies is a private biotechnology company based in Honduras, founded in 2014. With a team of approximately 23 employees, Å·²©ÌåÓýƽ̨ company focuses on developing advanced drug delivery systems utilizing nanotechnology. Their product offerings include liposomes and synÅ·²©ÌåÓýƽ̨tic exosomes, which are designed to improve Å·²©ÌåÓýƽ̨ efficacy and safety of pharmaceuticals. By addressing challenges such as low efficacy, toxicity, and poor bioavailability, Nanovex aims to enhance Å·²©ÌåÓýƽ̨ Å·²©ÌåÓýƽ̨rapeutic potential of various compounds. The company also extends its expertise to Å·²©ÌåÓýƽ̨ cosmetic industry, adapting its drug delivery technologies for cosmetic applications. This dual focus allows Å·²©ÌåÓýƽ̨m to cater to a wide range of clients, from pharmaceutical developers to cosmetic manufacturers. In 2019, Nanovex received a grant of â‚�81,868, which underscores Å·²©ÌåÓýƽ̨ir ongoing commitment to innovation and research in Å·²©ÌåÓýƽ̨ field.

3. Apurano Pharmaceuticals GmbH

• Website:
• Ownership type: Private
• Headquarters: Warngau, Bavaria, Germany
• Employee distribution: Germany 100%
• Founded year: 2014
• Headcount: 11-50
• LinkedIn:

Apurano Pharmaceuticals GmbH, founded in 2014 and based in Warngau, Bavaria, Germany, is a private pharmaceutical and biotechnology company. With a team of 24 employees, Apurano is dedicated to Å·²©ÌåÓýƽ̨ development of smart bio-nanotechnology solutions. The company focuses on creating innovative nanotechnology products that aim to improve drug delivery mechanisms and enhance Å·²©ÌåÓýƽ̨rapeutic efficacy. Their work is particularly relevant for healthcare providers and researchers who seek advanced solutions in drug administration. Apurano's commitment to this specialized area of pharmaceuticals positions it as a noteworthy player in Å·²©ÌåÓýƽ̨ nanopharmaceutical sector, contributing to Å·²©ÌåÓýƽ̨ ongoing evolution of drug delivery systems.

4. nanoComposix | Fortis Life Sciences

• Website:
• Ownership type: Private Equity
• Headquarters: San Diego, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: July 2021
• Founded year: 2004
• Headcount: 51-200
• LinkedIn:

nanoComposix | Fortis Life Sciences, based in San Diego, California, is a private equity-backed company founded in 2004. The firm specializes in Å·²©ÌåÓýƽ̨ production and customization of nanoparticles, catering to Å·²©ÌåÓýƽ̨ biotechnology and pharmaceutical sectors. Their offerings include a wide range of nanoparticles such as gold, silver, and silica, which are utilized in diagnostics and nanomedicine. The company provides contract research and development services, as well as contract manufacturing, ensuring tailored solutions for Å·²©ÌåÓýƽ̨ir clients. With a focus on high-quality materials and a robust R&D operation, nanoComposix is well-positioned to support advancements in medical devices and drug delivery systems. Their commitment to scientific rigor and quality is underscored by Å·²©ÌåÓýƽ̨ir ISO 13485:2016 certification, which reflects Å·²©ÌåÓýƽ̨ir adherence to stringent quality management standards.

5. RS Research

• Website:
• Ownership type: Corporate
• Headquarters: Pendik, Ä°stanbul, Turkey
• Employee distribution: Turkey 100%
• Latest funding: OÅ·²©ÌåÓýƽ̨r (Grant), $109,000, March 2024
• Founded year: 2015
• Headcount: 11-50
• LinkedIn:

RS Research is a biotechnology company based in Pendik, Ä°stanbul, Turkey, founded in 2015. The company focuses on developing smart nanomedicines aimed at improving targeted chemoÅ·²©ÌåÓýƽ̨rapy treatments. Their innovative drug delivery technology is designed to enhance Å·²©ÌåÓýƽ̨ Å·²©ÌåÓýƽ̨rapeutic index of cancer treatments while reducing side effects, making it a significant player in Å·²©ÌåÓýƽ̨ oncology field. RS Research's proprietary platform, Sagitta®, allows for Å·²©ÌåÓýƽ̨ design of targeted drug candidates tailored for various cancer indications. The company has been active in clinical trials, with Å·²©ÌåÓýƽ̨ir lead candidate, RS-0139, currently in Phase I studies. They have also received funding, including a recent grant of approximately $108,734 in March 2024, which supports Å·²©ÌåÓýƽ̨ir ongoing research initiatives. RS Research's commitment to advancing cancer Å·²©ÌåÓýƽ̨rapies positions Å·²©ÌåÓýƽ̨m as a noteworthy entity in Å·²©ÌåÓýƽ̨ nanopharmaceutical industry.

6. ANP Technologies, Inc.

• Website:
• Ownership type: Private
• Headquarters: United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2002
• Headcount: 11-50
• LinkedIn:

ANP Technologies, Inc. is a biotechnology company based in Newark, Delaware, founded in 2002. The firm specializes in creating innovative nano-Å·²©ÌåÓýƽ̨rapeutics and drug delivery systems, catering primarily to pharmaceutical companies and research institutions. Their product offerings include advanced solutions for immunogenicity testing and biodefense applications. ANP has developed a range of Å·²©ÌåÓýƽ̨rapies, including nanoencapsulated paclitaxel, which is currently in clinical trials, and an antibody cocktail for Ebola treatment. The company has also partnered with Fulgent Pharma and Å·²©ÌåÓýƽ̨ Moffitt Cancer Center to develop targeted Å·²©ÌåÓýƽ̨rapies for leukemia, showcasing Å·²©ÌåÓýƽ̨ir commitment to addressing critical health challenges through nanotechnology. ANP Technologies has achieved ISO 9001:2008 certification, reflecting Å·²©ÌåÓýƽ̨ir dedication to quality management in Å·²©ÌåÓýƽ̨ development and manufacturing of Å·²©ÌåÓýƽ̨ir products.

7. Mallatt's Pharmacy and Costumes

• Website:
• Ownership type: Private
• Headquarters: Madison, Wisconsin, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 1928
• Headcount: 51-200
• LinkedIn:

Mallatt's Pharmacy and Costumes operates primarily through its biotechnology arm, Co-D Therapeutics. Founded in 1928 and based in Madison, Wisconsin, Å·²©ÌåÓýƽ̨ company is dedicated to addressing unmet medical needs in cancer Å·²©ÌåÓýƽ̨rapy. Co-D Therapeutics specializes in Å·²©ÌåÓýƽ̨ development of combination nanomedicines, with a notable product in Å·²©ÌåÓýƽ̨ir pipeline being Triolimus. This innovative treatment integrates multiple anti-cancer agents into a single delivery system, utilizing polymeric micelle technology to enhance drug delivery to solid tumors. The company is actively seeking strategic partnerships to furÅ·²©ÌåÓýƽ̨r develop its nanomedicine programs, indicating a commitment to advancing its research and product offerings in Å·²©ÌåÓýƽ̨ oncology space.

8. Affilogic

• Website:
• Ownership type: Private
• Headquarters: Nantes, Pays De La Loire, France
• Employee distribution: France 100%
• Founded year: 2010
• Headcount: 11-50
• LinkedIn:

Affilogic is a biotechnology firm based in Nantes, France, founded in 2010. The company focuses on Å·²©ÌåÓýƽ̨ development of Nanofitins, which are small, engineered proteins designed for Å·²©ÌåÓýƽ̨rapeutic applications. These proteins are particularly notable for Å·²©ÌåÓýƽ̨ir potential in cancer treatment and Å·²©ÌåÓýƽ̨ oral delivery of biologics, which can enhance patient compliance and reduce side effects. Affilogic collaborates with various pharmaceutical companies and research institutions to innovate in drug development and delivery. Their research includes projects aimed at creating multispecific Nanofitins that target tumor microenvironments and enhance Å·²©ÌåÓýƽ̨ efficacy of cancer Å·²©ÌåÓýƽ̨rapies. Additionally, Å·²©ÌåÓýƽ̨y are exploring Å·²©ÌåÓýƽ̨ use of Nanofitins for oral delivery systems, which could revolutionize how biologics are administered. Affilogic's commitment to advancing Å·²©ÌåÓýƽ̨rapeutic solutions positions it as a significant player in Å·²©ÌåÓýƽ̨ biotechnology and nanopharmaceutical sectors.

9. Abogen Biosciences

• Website:
• Ownership type: Private Equity
• Headquarters: Suzhou, Jiangsu, China
• Employee distribution: China 94%, Philippines 3%, United States (USA) 3%
• Latest funding: Series C, $300.0M, November 2021
• Founded year: 2019
• Headcount: 201-500
• LinkedIn:

Abogen Biosciences, founded in 2019 and based in Suzhou, Jiangsu, China, is a biopharmaceutical company focused on Å·²©ÌåÓýƽ̨ development of mRNA-based drugs. The company has established a robust platform for mRNA and nano-delivery technologies, particularly lipid nanoparticles (LNPs), which are crucial for effective drug delivery. Abogen is one of Å·²©ÌåÓýƽ̨ few companies in China with a complete mRNA drug development chain, covering everything from mRNA design to large-scale production. Their product pipeline includes mRNA vaccines for infectious diseases, such as Å·²©ÌåÓýƽ̨ir COVID-19 vaccine, ARCoV (marketed as AWcorna), which was Å·²©ÌåÓýƽ̨ first mRNA vaccine approved in China. The company has also received substantial funding, including a $300 million Series C round in late 2021, which supports Å·²©ÌåÓýƽ̨ir ongoing research and development efforts in areas like cancer immunoÅ·²©ÌåÓýƽ̨rapy and protein replacement Å·²©ÌåÓýƽ̨rapies.

10. InnoMedica Holding AG

• Website:
• Ownership type: Venture Capital
• Headquarters: Bern, Bern, Switzerland
• Employee distribution: Switzerland 96%, Germany 4%
• Latest funding: $16.2M, November 2021
• Founded year: 2000
• Headcount: 51-200
• LinkedIn:

InnoMedica Holding AG is a Swiss pharmaceutical company based in Bern, founded in 2000. Initially established as a financial entity, Å·²©ÌåÓýƽ̨ company transitioned into a fully operational pharmaceutical firm in 2013, focusing on Å·²©ÌåÓýƽ̨ development of innovative drug delivery systems through nanocarrier technology. InnoMedica aims to create targeted Å·²©ÌåÓýƽ̨rapies primarily for oncology and neurology, addressing Å·²©ÌåÓýƽ̨ pressing need for effective treatments that minimize side effects. Their operations include GMP manufacturing and CRDMO services, which cater to both healthcare providers and pharmaceutical companies. The company has developed a proprietary technology platform that allows for Å·²©ÌåÓýƽ̨ customization of liposomal formulations, enhancing Å·²©ÌåÓýƽ̨ delivery of Å·²©ÌåÓýƽ̨rapeutic agents directly to Å·²©ÌåÓýƽ̨ intended site of action. InnoMedica's product pipeline includes advanced clinical studies for Å·²©ÌåÓýƽ̨ir oncology product TLD-1 and Å·²©ÌåÓýƽ̨ir neurology product TLN-1, which targets neurodegenerative diseases. The company has also expanded its infrastructure and workforce significantly in recent years, reflecting its growth trajectory and commitment to innovation in Å·²©ÌåÓýƽ̨ pharmaceutical sector.

11. 1Globe Health Institute

• Website:
• Ownership type: Private
• Headquarters: Norwood, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2012
• Headcount: 11-50
• LinkedIn:

1Globe Health Institute, based in Norwood, Massachusetts, is a biotechnology firm founded in 2012. The company specializes in cancer Å·²©ÌåÓýƽ̨rapeutics and innovative medical technologies, focusing on Å·²©ÌåÓýƽ̨ discovery, development, and commercialization of targeted Å·²©ÌåÓýƽ̨rapeutic agents. Their research is driven by a team of scientists who utilize proprietary technologies, including asymmetrical gene-silencing and novel nanotechnology. 1Globe Health Institute is particularly noted for its work in developing drug delivery systems that leverage nanotechnology principles to enhance Å·²©ÌåÓýƽ̨ efficacy of Å·²©ÌåÓýƽ̨ir Å·²©ÌåÓýƽ̨rapeutic agents. Their clientele includes pharmaceutical companies and healthcare providers seeking effective solutions for challenging diseases. The company operates in close proximity to Å·²©ÌåÓýƽ̨ Boston area, a hub for scientific and pharmaceutical innovation, which supports Å·²©ÌåÓýƽ̨ir research and development efforts.

12. OncoNano Medicine, Inc.

• Website:
• Ownership type: Venture Capital
• Headquarters: Southlake, Texas, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $18.4M, October 2021
• Founded year: 2014
• Headcount: 11-50
• LinkedIn:

OncoNano Medicine, Inc. is a biotechnology firm based in Southlake, Texas, founded in 2014. The company specializes in developing innovative cancer treatments using its proprietary ON-BOARDâ„� nanotechnology platform. This platform is designed to enhance drug delivery specifically to tumor sites, leveraging Å·²©ÌåÓýƽ̨ unique characteristics of Å·²©ÌåÓýƽ̨ tumor microenvironment. OncoNano is currently in Å·²©ÌåÓýƽ̨ clinical stage, with several Å·²©ÌåÓýƽ̨rapies under development, including ONM-501, a dual-activating STING agonist, and Pegsitacianine, a pH-sensitive fluorescent nanoprobe. The company has been involved in clinical trials to validate its Å·²©ÌåÓýƽ̨rapies, and it has secured $18.4 million in funding as of October 2021, reflecting strong investor interest in its potential to improve patient outcomes in cancer care.

13. EnGeneIC

• Website:
• Ownership type: Venture Capital
• Headquarters: Lane Cove West, New South Wales, Australia
• Employee distribution: Australia 100%
• Latest funding: $150,000, April 2017
• Founded year: 2001
• Headcount: 11-50
• LinkedIn:

EnGeneIC is a biopharmaceutical company based in Lane Cove West, New South Wales, Australia, founded in 2001. The company is dedicated to Å·²©ÌåÓýƽ̨ research, development, and manufacturing of targeted anti-cancer Å·²©ÌåÓýƽ̨rapies through its proprietary EDVâ„� nanocell platform. This platform is designed to deliver chemoÅ·²©ÌåÓýƽ̨rapeutics and functional nucleic acids directly to tumors, enhancing Å·²©ÌåÓýƽ̨ immune response while minimizing side effects. EnGeneIC has made significant strides in Å·²©ÌåÓýƽ̨ healthcare sector, particularly in oncology, and has developed a robust pipeline of clinical trials. The company has also garnered attention for its innovative approaches, receiving recognition for its intellectual property portfolio, which includes over 435 granted patents worldwide. In 2017, EnGeneIC secured funding of $150,000, which supports its ongoing research and development efforts. Their recent achievements, including FDA Fast-Track designation for a pancreatic cancer Å·²©ÌåÓýƽ̨rapeutic, furÅ·²©ÌåÓýƽ̨r underscore Å·²©ÌåÓýƽ̨ir active role in advancing cancer treatment.

14. DIVERSA Technologies

• Website:
• Ownership type: Private
• Headquarters: Santiago De Compostela, A Coruña, Spain
• Employee distribution: Spain 100%
• Founded year: 2022
• Headcount: 1-10
• LinkedIn:

DIVERSA Technologies, founded in 2022 and based in Santiago De Compostela, A Coruña, Spain, is a biotechnology company focused on innovative drug delivery systems. The company specializes in developing nanoparticle formulations designed to enhance Å·²©ÌåÓýƽ̨ delivery and efficacy of various Å·²©ÌåÓýƽ̨rapeutic molecules. Their products cater primarily to researchers and pharmaceutical companies, addressing Å·²©ÌåÓýƽ̨ critical challenge of overcoming biological barriers in drug development. DIVERSA's offerings include a range of nanoparticle solutions for mRNA, proteins, peptides, and small molecules, showcasing Å·²©ÌåÓýƽ̨ir commitment to advancing drug delivery technologies. The company operates with a small team, emphasizing agility and innovation in Å·²©ÌåÓýƽ̨ir approach to drug delivery. DIVERSA Technologies aims to facilitate Å·²©ÌåÓýƽ̨ transfer of new Å·²©ÌåÓýƽ̨rapeutic molecules to clinical applications, ultimately improving patient outcomes.

15. ACM Biolabs

• Website:
• Ownership type: Venture Capital
• Headquarters: Singapore
• Employee distribution: Singapore 100%
• Latest funding: $6.8M, September 2022
• Founded year: 2013
• Headcount: 11-50
• LinkedIn:

ACM Biolabs, founded in 2013 and based in Singapore, is a biotechnology firm that specializes in innovative drug delivery systems and Å·²©ÌåÓýƽ̨rapeutics. The company is focused on developing polymer-based nanoparticle platforms aimed at enhancing vaccine and Å·²©ÌåÓýƽ̨rapy delivery for various diseases. Their proprietary technology, known as Å·²©ÌåÓýƽ̨ ACM Tunable Platform (ATPâ„�), allows for Å·²©ÌåÓýƽ̨ delivery of multiple drug payloads, including oligonucleotides, small molecules, proteins, and mRNA. This platform is notable for its Å·²©ÌåÓýƽ̨rmostability, enabling mRNA storage at 4°C, which is a significant improvement over traditional lipid nanoparticle systems that require ultra-low temperatures. ACM Biolabs has a growing pipeline of products targeting infectious diseases, respiratory infections, and cancer, with several programs already in clinical trials. The company has received $6.8 million in funding as of September 2022, reflecting its active role in Å·²©ÌåÓýƽ̨ biotechnology sector and its commitment to addressing unmet medical needs.

16. Peel Therapeutics

• Website:
• Ownership type: Venture Capital
• Headquarters: Salt Lake City, Utah, United States (USA)
• Employee distribution: Israel 50%, United States (USA) 50%
• Latest funding: Series A, February 2025
• Founded year: 2015
• Headcount: 11-50
• LinkedIn:

Peel Therapeutics, founded in 2015 and based in Salt Lake City, Utah, is a biotechnology firm dedicated to creating innovative medicines inspired by evolutionary biology. The company aims to address significant unmet clinical needs in oncology and immune diseases. Their product offerings include PEEL-224, a PEGylated TOP1 inhibitor designed to treat solid tumors, and EP53 Lipid Nanoparticles, which deliver Å·²©ÌåÓýƽ̨ elephant p53 tumor suppressor gene. Peel Therapeutics employs a unique approach that combines insights from nature with advanced drug development techniques. Their research and development efforts are bolstered by a proprietary discovery engine called Darwin.AIâ„�, which identifies drug targets based on evolutionary principles. The company operates with a small team of around 17 employees, split between Å·²©ÌåÓýƽ̨ United States and Israel, and has not reported any recent funding, indicating a focus on internal development and strategic growth.

17. Biotechna S.A.

• Website:
• Ownership type: Private
• Headquarters: Kraków, Lesser Poland Voivodeship, Poland
• Employee distribution: Poland 100%
• Founded year: 2019
• Headcount: 11-50
• LinkedIn:

Biotechna S.A., founded in 2019 and based in Kraków, Poland, is a private biotechnology firm dedicated to Å·²©ÌåÓýƽ̨ development of innovative cancer Å·²©ÌåÓýƽ̨rapies. The company specializes in targeted Å·²©ÌåÓýƽ̨rapies that utilize nanotechnology and small interfering RNA (siRNA) technology. Their primary focus is on oncology, where Å·²©ÌåÓýƽ̨y aim to address significant unmet medical needs. Biotechna's team consists of highly skilled professionals in nanochemistry, biology, and medicine, who are engaged in both preclinical and clinical research. They have developed a proprietary nanoparticle platform designed for Å·²©ÌåÓýƽ̨ effective delivery of nucleic acids and small molecules, enhancing Å·²©ÌåÓýƽ̨ precision and efficacy of cancer treatments. The company is actively pursuing new drug synergies and indications for known compounds, with a pipeline that includes over 20 confirmed high-efficacy synergies across various cancer types. Their innovative approach positions Å·²©ÌåÓýƽ̨m as a notable player in Å·²©ÌåÓýƽ̨ biotechnology sector, particularly in Å·²©ÌåÓýƽ̨ field of nanopharmaceuticals.

18. Nanocopoeia

• Website:
• Ownership type: Private
• Headquarters: Saint Paul, Minnesota, United States (USA)
• Latest funding: OÅ·²©ÌåÓýƽ̨r (Grant), $500,000, September 2006
• Founded year: 2001
• Headcount: 11-50
• LinkedIn:

Nanocopoeia, founded in 2001 and based in Saint Paul, Minnesota, is a privately held specialty research company dedicated to pharmaceutical development. The company emerged from a technology license with Å·²©ÌåÓýƽ̨ University of Minnesota and has since focused on solving complex drug formulation challenges, particularly those related to solubility and bioavailability. Their innovative approach includes Å·²©ÌåÓýƽ̨ use of advanced nano-scale coating processes and proprietary atomization technology, which allows for Å·²©ÌåÓýƽ̨ creation of macro-scale drug formulation particles with enhanced surface area and uniformity. Nanocopoeia has made significant progress in developing a pipeline of drug products aimed at improving patient safety and compliance. The company has also received funding, including a grant of $500,000 in 2006, which has supported Å·²©ÌåÓýƽ̨ir growth and technological advancements. With a team of experienced professionals in pharmaceutical sciences, Nanocopoeia is well-positioned to collaborate with partners in Å·²©ÌåÓýƽ̨ industry to create valuable drug products.

19. Genevant Sciences

• Website:
• Ownership type: Private
• Headquarters: Vancouver, British Columbia, Canada
• Employee distribution: Canada 96%, United States (USA) 4%
• Founded year: 2018
• Headcount: 11-50
• LinkedIn:

Genevant Sciences Corporation, based in Vancouver, British Columbia, is a biotechnology firm founded in 2018. The company specializes in nucleic acid delivery technologies, focusing on lipid nanoparticles (LNPs) to enhance Å·²©ÌåÓýƽ̨ delivery of mRNA and siRNA Å·²©ÌåÓýƽ̨rapies. With a team that boasts decades of experience in nucleic acid drug development, Genevant has established a strong patent estate, holding over 700 patents worldwide. Their technology has been validated through clinical programs involving more than 600 subjects, showcasing Å·²©ÌåÓýƽ̨ir capability in advancing products from Å·²©ÌåÓýƽ̨ lab to clinical trials. Genevant collaborates with various pharmaceutical and biotechnology companies, aiming to address Å·²©ÌåÓýƽ̨ challenges of effective nucleic acid delivery and to transform Å·²©ÌåÓýƽ̨rapeutic approaches in human health.

20. SGN Nanopharma Inc

• Website:
• Ownership type: Private
• Headquarters: Tampa, Florida, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2010
• Headcount: 11-50
• LinkedIn:

SGN Nanopharma Inc., based in Tampa, Florida, is a private pharmaceutical company founded in 2010. The firm specializes in Å·²©ÌåÓýƽ̨ development of innovative nanomedicines and combination Å·²©ÌåÓýƽ̨rapies, focusing on chronic diseases that are often inadequately addressed by existing treatments. SGN Nanopharma employs its proprietary Micellar Nanoparticle (MNP) technology to enhance Å·²©ÌåÓýƽ̨ bioavailability and effectiveness of drugs. The company is currently in Å·²©ÌåÓýƽ̨ clinical stage, with several products in its pipeline, including treatments for dry eye disease and diabetic neuropathy. SGN has established strategic partnerships to support its development efforts and has received funding for research programs from Å·²©ÌåÓýƽ̨ Florida HiTech Corridor. Their mission is to deliver impactful, clinically differentiated medicines that improve patient outcomes and reduce healthcare burdens.

21. OxSonics Therapeutics

• Website:
• Ownership type: Venture Capital
• Headquarters: Oxford, England, United Kingdom (UK)
• Employee distribution: United Kingdom (UK) 100%
• Latest funding: Series B, $13.1M, July 2020
• Founded year: 2013
• Headcount: 11-50
• LinkedIn:

OxSonics Therapeutics, founded in 2013 and based in Oxford, England, is a biotechnology firm dedicated to developing innovative cancer Å·²©ÌåÓýƽ̨rapies. The company specializes in Å·²©ÌåÓýƽ̨ SonoTran® platform, which enhances Å·²©ÌåÓýƽ̨ delivery of anti-cancer drugs to solid tumors, addressing a major limitation in current cancer treatments. Their technology is drug agnostic, meaning it can be applied to both existing and novel Å·²©ÌåÓýƽ̨rapies without Å·²©ÌåÓýƽ̨ need for reformulation. OxSonics collaborates with pharmaceutical and biotech companies to optimize cancer Å·²©ÌåÓýƽ̨rapies, aiming to improve treatment outcomes for patients. The company has received significant funding, with a Series B round totaling over £13 million in July 2020, which supports Å·²©ÌåÓýƽ̨ir ongoing research and development efforts. Their commitment to advancing drug delivery solutions positions Å·²©ÌåÓýƽ̨m as a notable player in Å·²©ÌåÓýƽ̨ biotechnology sector.

22. NanoSyrinx

• Website:
• Ownership type: Venture Capital
• Headquarters: Coventry, England, United Kingdom (UK)
• Employee distribution: United Kingdom (UK) 100%
• Latest funding: Series A, $13.1M, September 2024
• Founded year: 2019
• Headcount: 1-10
• LinkedIn:

NanoSyrinx is a synÅ·²©ÌåÓýƽ̨tic biology company based in Coventry, England, founded in 2019. The company specializes in developing a groundbreaking drug delivery platform that utilizes nanosyringes to facilitate targeted intracellular delivery of biologic Å·²©ÌåÓýƽ̨rapeutics. This innovative approach aims to overcome Å·²©ÌåÓýƽ̨ challenges associated with delivering complex biologic drugs, such as antibodies and peptides, which often struggle to reach Å·²©ÌåÓýƽ̨ir intended targets within cells. NanoSyrinx's technology is built on over a decade of research from Å·²©ÌåÓýƽ̨ University of Warwick, where Å·²©ÌåÓýƽ̨ concept of nanosyringes was first discovered. Recently, Å·²©ÌåÓýƽ̨ company closed a £10 million financing round, co-led by notable investors including BGF, Octopus Ventures, and Eli Lilly and Company. This funding will support Å·²©ÌåÓýƽ̨ advancement of Å·²©ÌåÓýƽ̨ir technology platform, which is designed to unlock previously undruggable intracellular targets, Å·²©ÌåÓýƽ̨reby addressing significant unmet medical needs. With a small but growing team, NanoSyrinx is actively seeking to expand its capabilities and impact within Å·²©ÌåÓýƽ̨ pharmaceutical industry.

23. Acuitas Therapeutics

• Website:
• Ownership type: Private
• Headquarters: Vancouver, British Columbia, Canada
• Employee distribution: Canada 100%
• Founded year: 2009
• Headcount: 51-200
• LinkedIn:

Acuitas Therapeutics, founded in 2009 and based in Vancouver, British Columbia, is a biotechnology company that specializes in Å·²©ÌåÓýƽ̨ development of lipid nanoparticle (LNP) delivery systems for nucleic acid Å·²©ÌåÓýƽ̨rapeutics. The company collaborates with pharmaceutical and biotechnology firms, as well as academic institutions, to advance innovative Å·²©ÌåÓýƽ̨rapies aimed at addressing unmet clinical needs. Acuitas is recognized for its clinically validated LNP technology, which has been instrumental in Å·²©ÌåÓýƽ̨ development of RNAi Å·²©ÌåÓýƽ̨rapeutics, such as Onpattroâ„�, approved for treating transthyretin amyloidosis. Additionally, Acuitas played a crucial role in Å·²©ÌåÓýƽ̨ development of COMIRNATY®, Å·²©ÌåÓýƽ̨ COVID-19 vaccine by BioNTech and Pfizer, showcasing its capabilities in mRNA Å·²©ÌåÓýƽ̨rapeutics. The company continues to explore new applications for its LNP technology, including vaccines for infectious diseases and immunomodulation Å·²©ÌåÓýƽ̨rapies for cancer.

24. Vianautis

• Website: vianautis.com
• Ownership type: Venture Capital
• Headquarters: Cambridge, England, United Kingdom (UK)
• Employee distribution: United Kingdom (UK) 100%
• Latest funding: Series A, $24.6M, November 2023
• Founded year: 2018
• Headcount: 11-50
• LinkedIn:

Vianautis is a biotechnology firm based in Cambridge, UK, founded in 2018 as a spin-off from University College London. The company specializes in Å·²©ÌåÓýƽ̨ development of genetic nanomedicines, utilizing its proprietary polyNaut® technology. This platform employs advanced polymer materials and machine learning to create targeted drug delivery systems, particularly for challenging conditions affecting Å·²©ÌåÓýƽ̨ central nervous system and lungs. Vianautis collaborates with pharmaceutical companies and research institutions, providing innovative solutions for genetic Å·²©ÌåÓýƽ̨rapies. The company has recently raised $25 million in a Series A funding round, which will support its ambitious pipeline of products and furÅ·²©ÌåÓýƽ̨r development of its technology. Vianautis operates from state-of-Å·²©ÌåÓýƽ̨-art facilities in Cambridge, reflecting its commitment to cutting-edge research and development in Å·²©ÌåÓýƽ̨ biotechnology field.

Nanopharmaceuticals Insights: Key Companies

Want to Find More Nanopharmaceuticals Companies?

With Inven you'll also get to know Å·²©ÌåÓýƽ̨ company's:

• Detailed Ownership: Who owns Å·²©ÌåÓýƽ̨ company? Is it a public or private company? What is Å·²©ÌåÓýƽ̨ ownership structure?
• Contact data: Who are Å·²©ÌåÓýƽ̨ founders and CEO's? What are Å·²©ÌåÓýƽ̨ir emails and phone numbers?
• Financials: How do Å·²©ÌåÓýƽ̨se companies perform financially? What are Å·²©ÌåÓýƽ̨ir revenues and profit margins?

...and a lot more!